LINAC

NexCore Group and Experience Senior Living Named Finalists for National Awards

Retrieved on: 
Thursday, January 11, 2024
LINAC, Patient, Architecture, Mob, Healthcare real estate, Culture, ESL, Science, Foot, Gallery, CO, Practice, Independent living, Assisted living, Nursing

DENVER, Jan. 11, 2024 /PRNewswire-PRWeb/ -- One healthcare facility and two senior living communities developed by NexCore Group, a national healthcare real estate investment and development company that focuses on custom-designed facilities and communities for healthcare providers, science and technology sectors and seniors housing, have been selected as finalists in the Healthcare Real Estate Insights (HREI) magazine's annual awards program. Headquartered in Denver, NexCore developed the projects in Prescott, AZ, Mechanicsville, VA, and Broomfield, CO.

Key Points: 
  • Jarrod Daddis , President of NexCore, remarked, "NexCore is honored to be recognized again by HREI with three finalists this year.
  • NexCore's senior living entity, Experience Senior Living (ESL), identified an underserved senior living market amidst aging communities in suburban Richmond, Virginia.
  • Experience Senior Living (ESL), NexCore's senior living entity, researched and realized an opportunity in the underserved Broomfield, Colorado market.
  • NexCore Group LLC is a national healthcare real estate investment and development company that focuses on acquiring, developing, owning, and managing purpose-built facilities for healthcare, science and technology, and senior living.

American Shared Hospital Services Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
Proton, AMS, EBITDA, Three Months, NYSE, Proton therapy, SAN, ASTRO, Investment, Orlando Health, Marketing, Webcast, Marine Hospital Service, MD Anderson Cancer Center, Conference, Cancer, Growth, Original equipment manufacturer, Nine Months, LINAC, Society, Overalls, Pharmaceutical industry, Video game, Cryptocurrency, Clothing, Lithium, Life insurance, Esprit, Radiosurgery, Neuroscience

SAN FRANCISCO, CA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems and services, today announced financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Operating income for the third quarter of 2023 was $90,000 compared to operating income of $448,000 in the third quarter of 2022.
  • Adjusted EBITDA, a non-GAAP financial measure, was $1,669,000 for the third quarter of 2023, compared to $1,966,000 for the third quarter of 2022.
  • Net income attributable to American Shared Hospital Services in the third quarter of 2023 was $118,000, or $0.02 per diluted share, compared to net income of $316,000, or $0.05 per diluted share, for the third quarter of 2022.
  • Adjusted EBITDA, a non-GAAP financial measure, was $1,669,000 for the third quarter of 2023, compared to $1,966,000 for the third quarter of 2022.

Axcelis Announces Shipments of Purion XE High Energy and Purion H High Current Implanters to DRAM Memory Chipmakers

Retrieved on: 
Thursday, December 7, 2023
LINAC, Axcelis Technologies, DRAM, Rare-earth element, 3D printing

BEVERLY, Mass., Dec. 7, 2023 /PRNewswire/ -- Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of innovative, high-productivity solutions for the semiconductor industry, announced today shipments of the Purion XE™ high energy and the Purion H™ high current implanters to multiple fabs in Korea and China to manufacture DRAM memory devices. The systems include a follow-on shipment to an existing customer in Korea, and the penetration of a new customer in China. The systems shipped in the fourth quarter of 2023.

Key Points: 
  • BEVERLY, Mass., Dec. 7, 2023 /PRNewswire/ -- Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of innovative, high-productivity solutions for the semiconductor industry, announced today shipments of the Purion XE™ high energy and the Purion H™ high current implanters to multiple fabs in Korea and China to manufacture DRAM memory devices.
  • The systems include a follow-on shipment to an existing customer in Korea, and the penetration of a new customer in China.
  • The Purion H has an innovative high current implanter architecture, featuring unique scanned spot beam technology, designed for advanced device applications.
  • Our Purion XE is the industry standard for today's demanding high energy recipes.

NexCore Group and Arizona Oncology Celebrate the Opening of New Cancer Center in Prescott, Arizona

Retrieved on: 
Wednesday, November 8, 2023
Science, Urology, McKesson Corporation, Surgical oncology, Breast cancer, CT, Cancer, LINAC, Patient, Google Images, HDR, Oncology, Hospital, Nursing, Medical imaging

DENVER, Nov. 8, 2023 /PRNewswire-PRWeb/ -- NexCore Group, a national healthcare, life sciences, and senior living real estate developer, celebrated the grand opening of a new cancer center October 27 serving the residents in Prescott, Arizona. Arizona Oncology, one of the largest medical groups in Arizona devoted exclusively to cancer care, and NexCore collaborated on the 23,000-square-foot facility which opened to the public in October 2023. The Arizona Oncology Cancer Center offers patients in the region convenient access to the latest cancer treatment services and technologies.

Key Points: 
  • The Arizona Oncology Cancer Center offers patients in the region convenient access to the latest cancer treatment services and technologies.
  • The Arizona Oncology Cancer Center offers patients in the region convenient access to the latest cancer treatment services and technologies.
  • "The Prescott community now has access to exceptional cancer care at the newly opened Arizona Oncology center, a project realized through the collaboration of NexCore Group with McKesson and US Oncology.
  • "The Prescott community now has access to exceptional cancer care at the newly opened Arizona Oncology center, a project realized through the collaboration of NexCore Group with McKesson and US Oncology", commented NexCore President Jarrod Daddis.

Re-Imagine Proton Therapy: Mevion Breaks Down Barriers at ASTRO 2023

Retrieved on: 
Thursday, September 28, 2023
Radiology, Biotechnology, Oncology, General Health, Health, Medical Devices, Health Technology, Other Health, Proton, Proton therapy, Health care, ASTRO, FIT, Radiation, ARC, Multimedia, Research, LINAC, FLASH, Patient, Cost, Annual general meeting, Varian Medical Systems, Entrepreneurship, Thomas Rockwell Mackie, Society, Clinical, Medical imaging

Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, will showcase products and solutions to re-imagine proton therapy by breaking down access barriers at the upcoming American Society of Radiation Oncology 65th Annual Meeting (ASTRO 2023).

Key Points: 
  • Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, will showcase products and solutions to re-imagine proton therapy by breaking down access barriers at the upcoming American Society of Radiation Oncology 65th Annual Meeting (ASTRO 2023).
  • View the full release here: https://www.businesswire.com/news/home/20230928893588/en/
    Mevion Booth #2435 at ASTRO 2023 (Photo: Business Wire)
    Key highlights from Mevion at the ASTRO 2023 Annual Meeting will include:
    Breaking Site and Cost Barriers: Mission Complete - FIT Proton Therapy in your LINAC Vault
    The MEVION S250-FIT Proton Therapy System™ is the world’s first proton therapy system designed to FIT in a conventional LINAC vault.
  • We have scaled proton therapy down in size and reduced costs and barriers of entry, making proton therapy more accessible to patients.”
    Mevion proton therapy experts will be available at Mevion Booth #2435 to explore ideas that expand access to proton therapy treatment technology in your community during the ASTRO 65th Annual Meeting on October 1-3, 2023 in San Diego, CA.
  • *The MEVION S250-FIT Proton Therapy System, FLASH therapy, online adaptive therapy, and ARC therapy are not yet available for clinical use.

Navigating the Future of Radiosurgery: In-Depth Market Insights, Trends, and Geographic Coverage for Improved Healthcare Strategies - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 27, 2023
Surgery, Health, ASP, Face, Neoplasm, COVID-19, Radiosurgery, Segment, Incidence, SWOT, Hospital, LINAC, Patient, Microsoft Excel, SWOT analysis, Linear particle accelerator, Recession, Procedure, Retail, Pharmaceutical industry, Medical imaging

The Radiosurgery Systems market, part of the Neurology Devices therapeutic area, has shown resilience in the face of challenges.

Key Points: 
  • The Radiosurgery Systems market, part of the Neurology Devices therapeutic area, has shown resilience in the face of challenges.
  • This report offers a comprehensive analysis of the Radiosurgery Systems market, examining its size, segmentation, trends, and the impact of COVID-19.
  • The Radiosurgery Systems market comprises two primary segments: Linear Accelerator (LINAC) Radiosurgery Systems and GammaKnife Radiosurgery Systems.
  • Qualitative and quantitative information is available on global and regional trends, as well as unique country-specific insights into the Radiosurgery Systems market.

American Shared Hospital Services Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 14, 2023
Proton, Operating cost, Esprit, Partnership, Upgrade, Meridian International Center, Interest, Marketing, Proton therapy, Elekta, AMS, Overalls, GK, Cancer, Chemical engineering, Social media, LINAC, EBITDA, Investment, Radiosurgery, Webcast, HVS Global Hospitality Services, Growth, Orlando Health, Three Months, NYSE, MD Anderson Cancer Center, Pharmaceutical industry, Video game, Cryptocurrency, Clothing, Lithium

SAN FRANCISCO, CA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems and services, today announced financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Operating loss for the second quarter of 2023 was $325,000 compared to operating income of $793,000 in the second quarter of 2022.
  • Adjusted EBITDA, a non-GAAP financial measure, was $1,938,000 for the second quarter of 2023, compared to $2,129,000 for the second quarter of 2022.
  • Net loss attributable to American Shared Hospital Services in the second quarter of 2023 was $111,000, or $(0.02) per diluted share, compared to net income of $497,000, or $0.08 per diluted share, for the second quarter of 2022, and net income of $188,000, or $0.03 per diluted share, reported in the first quarter of 2023.
  • Adjusted EBITDA, a non-GAAP financial measure, was $1,938,000 for the second quarter of 2023, compared to $2,129,000 for the second quarter of 2022.

Leading Companies in the Global Stereotactic Surgery Devices Market, Including CyberKnife and PBRT, Expected to Contribute to Market Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 26, 2023
Surgery, Health, Medical Devices, Cyberknife, PBRT, COVID-19, Liver, Cancer, Research, USD, Government, Organization, Radiation, Hospital, LINAC, Investment, Patient, Disease, Diagnosis, Mortality, Growth, Pharmaceutical industry, Breast

The global stereotactic surgery devices market size is projected to reach USD 34.47 billion by 2030, expanding at 3.9% CAGR from 2023 to 2030.

Key Points: 
  • The global stereotactic surgery devices market size is projected to reach USD 34.47 billion by 2030, expanding at 3.9% CAGR from 2023 to 2030.
  • Increasing demand for minimally invasive surgeries, new product launches, and increasing investments in radiotherapy to improve oncology treatment are key factors driving the demand for stereotactic surgery devices industry.
  • This is also leading to stereotactic surgery devices replacing conventional invasive procedures.
  • The COVID-19 pandemic negatively impacted the market and led to a sharp fall in sales of stereotactic surgery devices.

Global Radiation Therapy Market Forecast Report 2023-2027: A $13.28 Billion Market in 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 26, 2023
Health, Pharmaceutical, Proton, Urbanization, Hitachi, Ion Beam Applications, Hospital, COVID-19, Ageing, Radiation, IGRT, Radiosurgery, Particle accelerator, Incidence, US, Proton therapy, Growth, IMRT, Medical imaging, Tomotherapy, LINAC

The "Global Radiation Therapy Market with Focus on LINAC: Insights & Forecast (2023-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Radiation Therapy Market with Focus on LINAC: Insights & Forecast (2023-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The global radiation therapy market is expected to reach US$13.28 billion in 2027, witnessing growth at a CAGR of 6.77%, over the period 2023-2027.
  • The global radiation therapy market can be categorized into external beam radiation therapy, internal beam radiation therapy and others (systemic radiotherapy) on the basis of type.
  • Depending upon the type, the global external beam radiation therapy market can be categorized into following categories: Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), Tomotherapy, Stereotactic Radiosurgery, Stereotactic Body Radiation Therapy and Proton Therapy.

United Imaging Unveils a Full Portfolio of Products at CMEF 2023, Highlighting Its AI Capabilities across Modalities

Retrieved on: 
Wednesday, May 17, 2023
Yale University, Blockchain, University, Moses Austin, Freedom, MI, Dow International Medical College, 3D, UDP, Research, Multimedia, MR, DSA, Washington University in St. Louis, 2D, Movement, Umi, Radiation, Hospital, LINAC, Neurosurgery, Scan, ACS, Patient safety, PET/CT, PET/MR, Neoplasm, AI, RT, AR, ASIC, Medical imaging, Medical device

SHANGHAI, May 17, 2023 /PRNewswire/ -- United Imaging unveiled its full range of products, including PET/CT, PET/MR, MR, CT, DR, RT, and digital solutions, at the China International Medical Equipment Fair (CMEF) recently, highlighting the products' AI capacity across modalities.

Key Points: 
  • SHANGHAI, May 17, 2023 /PRNewswire/ -- United Imaging unveiled its full range of products, including PET/CT, PET/MR, MR, CT, DR, RT, and digital solutions, at the China International Medical Equipment Fair (CMEF) recently, highlighting the products' AI capacity across modalities.
  • Many of the offerings incorporated AI capabilities, which are designed to provide clinicians with more accurate and efficient tools for diagnosing and treating a variety of clinical scenarios.
  • One standout product was the uRT-linac 506c, an innovative medical linear accelerator (LINAC) device from United Imaging.
  • Moving forward, United Imaging Group will leverage the power of our super innovation cluster to expand beyond imaging and promote integration within medical treatment.